Canaccord Genuity Maintains a 'Buy' on OraSure Technologies (OSUR); Focus on 2012 Catalysts

Canaccord Genuity maintains a 'Buy' on OraSure Technologies (NASDAQ: OSUR) price target of $14.00.

Analyst, Jeffrey Frelick, said, "We reiterate our rating on OSUR following in-line Q1 results, early traction with new rapid HCV test, and an upcoming FDA panel...012 potential catalysts. 1) Change in the recommended HCV testing guidelines H1/12; 2) Quarterly HCV sales demonstrating uptake; 3) Positive FDA advisory panel in May for HIV-OTC; 4) Early FDA approval for HIV-OTC in H2/12."

For an analyst ratings summary and ratings history on OraSure Technologies click here. For more ratings news on OraSure Technologies click here.

Shares of OraSure Technologies closed at $11.07 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Nutanix (NTNX) PT Raised to $80 at Oppenheimer Into EPS
• Seaport Global Securities Upgrades Analog Devices (ADI) to Buy, 'appears to be entering the sweet part of the cycle'
• Raymond James Starts Southern California Bancorp (BCAL) at Outperform